Free tool
FAERS Monitor: Avlayah
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761485 or its brand name (Avlayah, Tividenofusp Alfa-Eknm). Reports on generic versions are filed under their own applications.
Reports
8
Serious
7
88% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infusion related reaction5
- cough3
- oxygen saturation decreased3
- urticaria3
- dyspnoea2
- chills1
- discomfort1
- erythema1
- eye swelling1
- flushing1
- hypopnoea1
- hypoxia1
- periorbital oedema1
- pruritus1
- pyrexia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypopnoea | 1 | 757.8 | 121.1 | 188 |
| periorbital oedema | 1 | 506.5 | 81.0 | 126 |
| infusion related reactionSignal | 5 | 198.3 | 115.9 | 797 |
| oxygen saturation decreasedSignal | 3 | 140.4 | 57.4 | 288 |
| hypoxia | 1 | 74.7 | 11.9 | 18 |
| eye swelling | 1 | 70.7 | 11.3 | 17 |
| urticariaSignal | 3 | 47.1 | 19.2 | 94 |
| discomfort | 1 | 43.1 | 6.9 | 10 |
| coughSignal | 3 | 28.1 | 11.5 | 54 |
| flushing | 1 | 25.9 | 4.1 | 6 |
| chills | 1 | 22.4 | 3.6 | 5 |
| erythema | 1 | 12.8 | 2.0 | 2 |
| dyspnoea | 2 | 9.3 | 2.8 | 8 |
| pyrexia | 1 | 7.6 | 1.2 | 1 |
| pruritus | 1 | 6.8 | 1.1 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.